Rapamycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-02627 |
CAS | 53123-88-9 |
Molecular Weight | 914.19 |
Molecular Formula | C51H79NO13 |
Purity | >98% |
Ordering Information
Catalog Number | Size | Price | Stock | Quantity |
---|---|---|---|---|
BBF-02627 | 500 mg | $199 | In stock |
Online Inquiry
Add to cartDescription
Rapamycin is an mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcriptional activation of cytokines.
Specification
Synonyms | Sirolimus; (-)-Rapamycin; AY 22989; AY-22989; I-2190A; NSC 226080; RAPA; RAP; RPM; SLM; WY-090217; Everolimus EP Impurity A |
Storage | Store at -20°C |
IUPAC Name | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone |
Canonical SMILES | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC |
InChI | InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1 |
InChI Key | QFJCIRLUMZQUOT-HPLJOQBZSA-N |
Source | Streptomyces hygroscopicus |
Properties
Appearance | White to off-white powder |
Application | antifungal and antineoplastic agent |
Antibiotic Activity Spectrum | fungi; neoplastics (Tumor) |
Boiling Point | 973.0°C at 760 mmHg |
Melting Point | 183-185°C |
Flash Point | 542.261°C |
Density | 1.2 g/cm3 |
Solubility | Soluble in DMSO (25 mg/ml), ethanol (up to 50 mg/ml), chloroform (5 mg/ml), methanol (25 mg/ml), ether, and acetone. Limited water solubility. |
LogP | 4.3 |
Toxicity
Carcinogenicity | No indication of carcinogenicity to humans (not listed by IARC). |
Mechanism Of Toxicity | Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle. |
Toxicity | LD50: >800 mg/kg (oral, rat); LD50: >800 mg/kg (oral, mice). |
Reference Reading
Spectrum
Predicted LC-MS/MS Spectrum - 10V, Positive
Experimental Conditions
Collision Energy: 10 eV
Instrument Type: QTOF (generic), spectrum predicted by CFM-ID
Mass Resolution: 0.0001 Da
Recommended Products
BBF-03816 | Milbemycin oxime | Inquiry |
BBF-03963 | Pristinamycin | Inquiry |
BBF-00968 | Homoalanosine | Inquiry |
BBF-03891 | Cefsulodin sodium | Inquiry |
BBF-03862 | Cefozopran hydrochloride | Inquiry |
BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2